Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Cancer Research|June 3, 2004
A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cellsMartin G Sauer, Marna E Ericson, Brenda J Weigel, et al.
Nature Medicine|April 26, 2011
GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in miceTibor Kempf, Alexander Zarbock, Christian Widera, et al.
Transplantation and Cellular Therapy|April 13, 2026
Survival trends in young adults with acute leukaemia after AHSCT in Germany: comparisons with younger and older patientsJochen J Frietsch, Sarah Flossdorf, Ashrafossadat Ahmadian, et al.
Lancet (London, England)|November 11, 2024
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trialJanet L Kwiatkowski, Mark C Walters, Suradej Hongeng, et al.
Bone Marrow Transplantation|February 7, 2024
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppressionBarbara Meissner, Peter Lang, Peter Bader, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2025
Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activityFranziska Baatz, Arnab Ghosh, Jessica Herbst, et al.
British Journal of Haematology|February 4, 2020
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 childrenTheodor Uden, Alice Bertaina, Jonas Abrahamsson, et al.
The New England Journal of Medicine|December 10, 2021
Betibeglogene Autotemcel Gene Therapy for Non-β<sup>0</sup>/β<sup>0</sup> Genotype β-ThalassemiaFranco Locatelli, Alexis A Thompson, Janet L Kwiatkowski, et al.
Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.
Cancer Research|June 5, 2013
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHDArnab Ghosh, Amanda M Holland, Yildirim Dogan, et al.
Pageof 5